CA3187578A1 - Method of treating aml subtypes using arginine-depleting agents - Google Patents

Method of treating aml subtypes using arginine-depleting agents

Info

Publication number
CA3187578A1
CA3187578A1 CA3187578A CA3187578A CA3187578A1 CA 3187578 A1 CA3187578 A1 CA 3187578A1 CA 3187578 A CA3187578 A CA 3187578A CA 3187578 A CA3187578 A CA 3187578A CA 3187578 A1 CA3187578 A1 CA 3187578A1
Authority
CA
Canada
Prior art keywords
arginine
depleting agent
leukemia
acute
aml
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3187578A
Other languages
English (en)
French (fr)
Inventor
Sui Yi Kwok
Norman Fung Man Wai
Terence Shau Yin WAI
Yun Chung Leung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vision Global Holdings Ltd
Original Assignee
Vision Global Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vision Global Holdings Ltd filed Critical Vision Global Holdings Ltd
Publication of CA3187578A1 publication Critical patent/CA3187578A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3187578A 2020-06-29 2020-06-29 Method of treating aml subtypes using arginine-depleting agents Pending CA3187578A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2020/098681 WO2022000151A1 (en) 2020-06-29 2020-06-29 Method of treating aml subtypes using arginine-depleting agents

Publications (1)

Publication Number Publication Date
CA3187578A1 true CA3187578A1 (en) 2022-01-06

Family

ID=79317763

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3187578A Pending CA3187578A1 (en) 2020-06-29 2020-06-29 Method of treating aml subtypes using arginine-depleting agents

Country Status (6)

Country Link
EP (1) EP4153167A4 (zh)
KR (1) KR20230104110A (zh)
CN (1) CN115697320A (zh)
CA (1) CA3187578A1 (zh)
TW (1) TW202206095A (zh)
WO (1) WO2022000151A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021110071A1 (en) * 2019-12-02 2021-06-10 The Hong Kong Polytechnic University Methods for inducing intermittent fasting and modulating autophagy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006015512A1 (fr) * 2004-08-11 2006-02-16 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Arginine déiminase modifiée
AU2012330497B2 (en) * 2012-04-04 2016-08-04 Polaris Group Methods of treating with arginine deiminase
WO2018009528A1 (en) * 2016-07-05 2018-01-11 Tdw Group Combination cancer immunotherapies with arginine depletion agents
CN110191721A (zh) * 2016-09-26 2019-08-30 集合集团控股公司 有淋巴系统失调的受试者中癌症的评估与治疗方法

Also Published As

Publication number Publication date
WO2022000151A1 (en) 2022-01-06
KR20230104110A (ko) 2023-07-07
CN115697320A (zh) 2023-02-03
TW202206095A (zh) 2022-02-16
EP4153167A4 (en) 2024-02-28
EP4153167A1 (en) 2023-03-29

Similar Documents

Publication Publication Date Title
Patel et al. Current advances in the treatment of BRAF-mutant melanoma
Guo et al. Thrombin-responsive, brain-targeting nanoparticles for improved stroke therapy
JP2011526626A5 (zh)
JP7373998B2 (ja) 有効性がより大きくかつ毒性がより少ない腫瘍標的指向方法及び試薬
JP2012504423A (ja) 治療用リボヌクレアーゼ
CN109963597B (zh) 聚乙二醇化血管内皮抑制素类似物及其应用
US20240076337A1 (en) Dual cytokine fusion proteins comprising il-10
WO2018210439A1 (en) Novel pharmaceutical composition comprising particles comprising a complex of a double-stranded polyribonucleotide and a polyalkyleneimine
WO2019213686A1 (en) Therapeutic compositions and uses therefor
Ward et al. Clinical experience of cancer immunotherapy integrated with oleic acid complexed with de-glycosylated vitamin D binding protein
US20210401952A1 (en) Method of treating AML subtypes using arginine-depleting agents
WO2022000151A1 (en) Method of treating aml subtypes using arginine-depleting agents
Su et al. Treatment of chemotherapy-induced neutropenia in a rat model by using multiple daily doses of oral administration of G-CSF-containing nanoparticles
Choi et al. Nanocages displaying SIRP gamma clusters combined with prophagocytic stimulus of phagocytes potentiate anti-tumor immunity
US20230287075A1 (en) Dual cytokine fusion proteins comprising multi-subunit cytokines
EP3142692B1 (en) Compositions comprising il-31 and uses thereof
JP2022513403A (ja) ジフテリア毒素－ヒトインターロイキン－３結合体と他の薬剤との組合せにより骨髄増殖性腫瘍を治療する併用療法の方法
US10874711B2 (en) Use of annexin V to reduce the spread of intracellular pathogens
KR20180129585A (ko) Mage-1에 특이적으로 결합하는 압타머 및 이의 용도
CN118715239A (zh) 包含多亚基细胞因子的双细胞因子融合蛋白
Nusbaum Potential use of IgA protease therapy in IgA myeloma patients